Table 7.

Grading scheme used for clinical practice recommendations

LevelStrengthEvidence basis
AStrongBased on strong scientific evidence; benefits clearly outweigh risks
BModerateBased on reduced confidence scientific evidence and expert opinion;
benefits likely to outweigh risks
COptionalBased mainly on expert opinion,
for use with evidence development in a research context

Table adapted from: Amstutz, U., N.H. Shear, M.J. Rieder, S. Hwang, et al., Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia, 2014. 55(4): p. 496-506 (5).

From: Carbamazepine Therapy and HLA Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.